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Abstract: Prospective cohort studies and animal models support the concept that low docosahexa-
enoic acid intake is implicated in the etiology or progression of Alzheimer’s disease. However, other
studies crucial to this relationship are less encouraging. To date, the few trials using docosahexaenoic
acid to treat declining cognition in the elderly have either been very small or, in the largest trial, the
beneficial effect was mild and limited to a sub-group of patients. The supplements used in each of these
clinical trials contained at least one polyunsaturated fatty acid other than docosahexaenoic acid, so the
active ingredient remains unclear. One widely cited study reported markedly lower brain docosahexae-
noic acid in Alzheimer’s disease but at least five other much less commonly cited reports have not
corroborated this effect. There are numerous inconsistencies or confounders in the data and several
challenges to overcome before definitively attributing a specific role to docosahexaenoic acid in the
protection of cognitive function in the elderly.
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Introduction
As the percentage of elderly people in devel-
oped countries increases, awareness is growing
rapidly about the pivotal importance of main-
taining physical and cognitive autonomy for
healthy aging. Alzheimer’s disease (AD) repre-
sents the main form of cognitive decline in the
adults. As such, preventing or avoiding the
main risk factors for AD improves the chances
of prolonging cognitive function and quality of
life in the elderly. Great efforts are now being
made to understand the etiology of AD and to
develop strategies to attenuate its significant
medical, social and economic impact. Cur-
rently, most treatment strategies for AD focus
on pharmacological interventions while most
strategies for prevention focus on lifestyle risk
factors, especially nutrition. According to a
recent European report [1], no single strategy
has been particularly successful at reducing the
incidence or growing socio-economic impact
of AD or other adult forms of significant cogni-
tive decline.
There is growing concern that once AD is clini-
cally diagnosed it is already too late to initiate
effective treatment. Hence, there is a burgeon-
ing interest in nutritional approaches to reduce
the risk of cognitive decline before it becomes
clinically symptomatic. Amongst the various
nutritional approaches, one that is gaining a lot
of attention at the moment relates to low
intake of fish and omega (x) 3 polyunsaturated
fatty acids as a risk factor for AD. The x3 fatty
acid most studied in the context of AD is
docosahexaenoic acid (DHA; 22:6x3), which is
found principally in fish and seafood. A possible
link between dietary DHA and maintenance of
brain function in adults has its origins in the
study of infant brain development where DHA
is now clearly recognized by most pediatric
societies and government regulatory agencies
as an essential component of optimal post-
natal feeding practice.
At present, we are aware of four reports
describing positive but very mild effects of a
dietary DHA supplement in AD or other forms
of cognitive deterioration in the elderly. In
addition, one report showing lower brain DHA
levels in AD is frequently cited. These studies
compliment a much larger epidemiological lit-
erature linking low x3 fatty acid and/or low
DHA intake to higher risk of AD, a literature
supported by several animal studies (which will
not be reviewed here). Despite the apparent
link between low DHA intake and AD, signifi-
cant confounders limit interpretation of the
studies reporting a clinical benefit of DHA in
AD. Several detailed reports of brain fatty acid
data in AD actually show no specific change or
even a rise in brain DHA, but are not commonly
cited. Hence, in the interests of encouraging a
more critical perspective on the putative link
between DHA and AD, we provide here a brief
review of the literature on clinical trials and
brain DHA data in AD.
Linking low DHA
and Alzheimer’s disease
A plausible association between DHA and risk
reduction for cognitive decline in the elderly is
emerging on three main fronts – epidemiologi-
cal studies, plasma DHA levels in AD patients,
and animal models. A task force of the Interna-
tional Association of Nutrition and Aging
recently reviewed the literature on nutritional
factors associated with aging-related cognitive
decline [2]. This report provided details of
15 prospective studies conducted between
1997-2006 that focused on whether the risk of
cognitive decline during aging is associated
with low intake of total dietary fat, fish,
and/or x3 fatty acids from fish. Collectively,
these studies followed up an average of
40,000 people over 6 years. Two of the largest
of these studies reported no significant associa-
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all showed a protective effect of fish and/or
DHA on risk of cognitive decline. Other reviews
[3] and a more recent epidemiological study
[4] also came to the same conclusion.
Because of the normally strong positive asso-
ciation between plasma DHA and DHA or fish
intake, it would be expected that a link
between low fish or DHA intake and cognitive
decline in the elderly would be reflected by
lower plasma DHA in those experiencing cog-
nitive decline. Indeed, several studies have
found low plasma DHA in AD [5-8], but one
study found that AD was accompanied by
higher plasma DHA [9].
Clinical efficacy of DHA
in Alzheimer’s disease
Regardless of the plausibility of a relationship
that emerges from other types of studies,
clearly, the central issue in linking low DHA to
risk of AD is whether higher DHA intake has a
lasting clinical beneficial effect in preventing or
reducing cognitive decline in any form of neu-
rodegeneration, most particularly in AD. No
other type of study can supplant the impor-
tance of a series of independently run, well-
designed clinical interventions that collectively
support a therapeutic benefit of DHA.
In the largest study to date, Freund-Levi et al.
[10] recently reported the results of a random-
ized, placebo-controlled, double blind trial, in
which a mixed supplement containing both
DHA (1.7 g/d) and eicosapentaenoic acid (EPA
– 20:5x3; 0.6 g/d) was given to patients with
mild to moderate AD. The patients continued
to receive their usual medication and received
the active treatment (DHA + EPA) or placebo
for 6 months followed by active treatment of
both groups for a further 6 months. In the
174 participants completing the 12 mo trial,
no difference in cognitive function between the
two groups was observed after the first 6
months. In a small sub-group with relatively
high cognitive function at the start of the
study, cognitive scores (mini-mental state
exam; MMSE) and delayed word recall
declined more slowly on the active treatment.
More rapid decline of the MMSE score during
the first 6 months in those with a starting
MMSE of < 24 was noted but was not statisti-
cally significant.
Three smaller trials using DHA in AD [11-13]
have been reported but two of these studies
appear to have only been published in prelimi-
nary form [11, 12]. Terano et al. [11] random-
ized 20 elderly vascular dementia patients in a
nursing home to receive no treatment or a DHA
supplement (4.3 g/d for 12 mo). Initially, these
patients all had cognitive evaluations consis-
tent with mild to moderate dementia. Depend-
ing on the cognitive test used, improvement in
the DHA group was seen at 3 and/or 6 mo, but
not at 12 mo. Suzuki et al. [12] evaluated the
effect of 680-800 mg/d of DHA in 22 elderly
patients with cognitive decline of mixed etiol-
ogy. In about half the patients, some cognitive
parameters improved during the 6 month trial.
Kotani et al. [13] evaluated the effect of a 90 d
treatment using a mixture providing a total of
240 mg/d of DHA and arachidonic acid (AA;
20:4x6) in patients with AD or mild cognitive
impairment (MCI). The proportion of DHA to
AA in the mixture was not given. AD patients
(n = 8) only received the active treatment. MCI
patients received either the active treatment
(DHA+AA; n = 12) or a placebo (6 capsules of
olive oil providing 240 mg/d; n = 9). Attention
and immediate memory scores improved in
the MCI group given DHA+AA but not in the
other groups.
Boston et al. [14] reported that there was no
effect of a 12 wk treatment with 1g/d ethyl-EPA
on several parameters of cognition in AD
patients who had a starting MMSE score of 19.
This report is noted here because it used one of
the fish oil x3 fatty acids (EPA) but this highly
purified preparation contained no DHA.
These clinical studies highlight several chal-
lenges associated with investigating a benefi-
cial effect of x3 fatty acids in AD. In all four of
these trials [10-13], more than one potentially
active polyunsaturate was present, so the ques-
tion arises as to whether the beneficial effect
due to DHA alone, or to the EPA [10-12] or AA
[13] also provided with the DHA, or to the
combinations of DHA + EPA or DHA + AA.
Assuming that half the active treatment in the
study by Kotani et al. [13] was DHA, what
explains how their results appear to be broadly
equivalent to those of Freund-Levi et al. [10]
who provided 14 times as much DHA, or those
of Terano et al. [11], who provided 36 times as
much DHA (120 mg/d versus 1.7 or 4.3 g/d,
respectively)? Since different tests of cognitive
function were employed and the supplements
were given for different periods, were these
interventions studies actually comparable? As
implied in the study by Freund-Levi et al. [10],
are those with higher cognitive function at the
start of the trial actually likely to benefit more
from a x3 supplement? Are those with lower
cognitive function actually at greater risk when
given a x3 supplement?
Brain levels of DHA
in Alzheimer’s disease
If DHA supplementation is beneficial in AD or
MCI, it seems reasonable to expect that this
benefit relates to correcting lower brain DHA.
Although we have found no reports of brain
DHA levels in humans after DHA supplementa-
tion (in AD or otherwise), we are aware of the
following reports on brain DHA content in AD:
Bowen et al. [15] appear to be the first to have
reported brain fatty acid data in AD. They
analyzed fatty acid profiles of phospholipids
from frontal grey matter from controls
(n = 12), senile dementia (n = 11), AD (n = 4)
and Creuzfeldt-Jacob disease (n = 1). Their
method pre-dated capillary gas chromatogra-
phy so did not permit good separation of spe-
cific polyunsaturates. As a result of this impor-
tant limitation, AA was grouped with adrenic
acid (22:4x6) and DHA was grouped with the
two docosapentaenoic acids. These data were
reported as ‘polyunsaturates’. They found no
age- or disease-related change in brain polyun-
saturates or phospholipid concentration.
In 1991, Soderberg et al. published the most
widely cited paper on fatty acid composition of
brain samples obtained at autopsy from
8-10 controls and AD patients [16]. Brain
samples were analyzed from four different
regions – frontal grey matter, white matter
(region not specified), hippocampus and pons.
Fatty acids were analyzed from two of the main
classes of phospholipids in the brain – phos-
phatidylethanolamine (PE) and phosphatidyl-
choline, which are rich and poor, respectively,
in polyunsaturated fatty acids. The % of DHA in
PE was reduced by up to 50% in all four brain
regions from patients with AD. The fatty acid
changes attributed to AD were not be due to
aging alone which, as they reported in the
same paper, was not associated with changes
in brain fatty acid composition.
In 1993, Skinner et al. [17] reported brain fatty
acid composition in 15 AD patients and
10 controls. Grey and white matter of frontal,
parietal and parahippocampal regions were
studied. Amongst the polyunsaturates, there
were no differences due to AD except for
3-4 fold higher levels of adrenic acid in grey
matter, as well as higher DHA in parietal white
matter.
In 1998, Corrigan et al. [18] reported the fatty
acid composition of parahippocampal cortex
in 8 AD patients and 6 age-matched controls.
AD was confirmed histologically in each case.
DHA was not different between AD and con-
trols for any of the four phospholipid classes or
in the cholesteryl ester class. In the AD samples,
adrenic acid was lower in both PE and phos-
phatidylserine, and AA was also lower in PE. In
the cholesteryl esters of AD brain, a-linolenic
acid (18:3x3) was present at only 5% of the
level seen in controls.
In 1998, Prasad et al. [19] evaluated brain fatty
acid composition in 9 AD patients and 9 age-
matched controls. Fatty acids were quantified
(nmol/g) in several brain regions and in three
phospholipid classes as well as in brain free
fatty acids. DHA was 45% lower in PE from the
hippocampus and parahippocampal gyrus
(both regions analyzed together), and was
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24% lower in the phosphatidylcholine fraction
of the cerebellum. Lower DHA in hippocampal
and parahippocampal PE was actually due to
lower PE because, on a percentage basis, DHA
was 50% higher in this lipid class. Otherwise,
DHA did not differ across lipid fractions or brain
regions. This study emphasized the possible
importance of lower plasmalogens, a form of
PE with vinyl-linked instead of ester-linked fatty
acids, in the progression of AD. In AD, a lower
concentration plasmalogens was observed but
only in the hippocampus [19].
In 1999, Guan et al. [20] reported the phos-
pholipid and fatty acid composition of brain
samples from AD patients (n = 15; 80 y old)
and controls (n = 13; 72 y old). Data were
provided for frontal cortex, hippocampus and
white matter and were expressed relative to
brain DNA. In the AD samples, the content of
the two main phospholipids was 16-24% lower
in the frontal cortex, an effect due primarily to
lower plasmalogen PE. Expressed in relation to
brain DNA content, DHA was not different in
the various lipid classes of frontal cortex from
AD patients compared to the controls. Given
that the concentration of plasmalogen PE in
the frontal cortex was decreased in AD brain
but the DHA concentration in plasmalogen PE
was unchanged, the % of DHA in this lipid class
actually increased somewhat. In contrast, AA
was decreased by 49% and adrenic acid was
decreased by 27% in the plasmalogen PE of
frontal cortex from AD patients. Oleic acid
(18:1x9) was also decreased by 25-75% in the
same regions, an effect not reported elsewhere.
In 2001, Han et al. [21] reported the fatty acid
composition of the various molecular species of
PE in several brain regions from AD patients
who were separated according to different lev-
els of cognitive decline (0.5 to 3 on the clinical
dementia rating scale. There were 6 samples in
the control group and in each of the four
grades of AD. They showed that even at the
earliest clinically defined stage of AD, plasmalo-
gen PE was decreased by up to 40% in white
matter. In gray matter, this decline in PE was
less severe but also correlated with clinical
severity. DHA concentrations (mg/g protein)
were lower in some brain regions as were other
fatty acids, including saturates, monounsat-
urates and x6 polyunsaturates. The only brain
region in which lower DHA was not due to
lower PE was in the cerebellum.
Taken collectively, published brain DHA data
are available from about 85 AD patients and
54 controls but it is impossible to draw any
clear conclusion about a direct link between
lower brain DHA and AD. When low DHA was
observed, it was not specific for DHA: either AA
and/or adrenic acid were also decreased [16,
18, 21], or the lower DHA was a function of a
decrease in one of the lipid classes, most com-
monly plasmalogen PE [20]. Increases of up to
50% for DHA [17, 19, 20] and 4 fold for adrenic
acid [17] have also been reported for some
regions of AD brain. Hence, it is clearly incor-
rect to discuss lower brain DHA as if it were a
commonly accepted or specific observation in
AD. These studies actually seem to agree more
about changes in brain phospholipids in AD,
particularly the decrease in plasmalogen PE,
which may be equally or more important as the
possible changes in their fatty acid composi-
tion [22]. Therefore, the comment made by
Guan et al. [20] nearly a decade ago still seems
highly pertinent – ‘these discrepancies are
largely due to diagnostic problems, method-
ological differences as well as to calculation and
presentation’.
Good data from age-matched controls are of
critical importance to interpreting changes in
brain lipid or fatty acid composition attribut-
able to AD. Svennerholm et al. [23] reported
age stratified data for brain composition from
people living at home who experienced acci-
dental deaths. They had 40-50 samples per age
group and showed that between the lowest
age group (20-39 y) and the highest
(80-100 y), brain weights decreased by 20%
and brain phospholipid content decreased by
about 43%. Nevertheless, no evaluation of
cognitive function or fatty acid composition
was reported. Soderberg et al. [16] reported
age-stratified data showing that aging alone
does not change brain fatty acid in either of the
two main phospholipid classes of the brain.
Therefore, agreement is lacking on even the
basic point of whether healthy aging is associ-
ated with a change in brain fatty acid compo-
sition [16, 23], so there is a real possibility that
some of the discrepancies regarding whether
or not brain DHA changes in AD may actually
be due to difficulty in selecting healthy, age-
matched controls or in classifying the AD
patients themselves. Subcellular changes in
DHA should be explored to see whether they
are partially responsible for the wide disparities
in reported effects of AD on brain DHA. The
reports of lower brain AA and adrenic acid in
AD should also not be overlooked because AA
may have clinically relevant effects on cogni-
tion [13].
Oversimplification
of the relation between DHA
and Alzheimer’s disease?
Assuming that low fish intake does in fact
increase the risk of AD, should low brain DHA
be necessarily expected in AD or, indeed, that
DHA would be clinically effective in AD? DHA
synthesis and b-oxidation are both very low in
humans [24, 25]. Therefore, unlike in many
animal models, in humans, DHA intake does
have an important effect on whole body DHA
homeostasis [26]. Nevertheless, dietary x3
fatty acid depletion studies show that relative
to DHA in blood or other tissues, brain DHA is
slower to deplete or to replete after dietary
depletion. Hence, in humans, the link between
DHA intake and brain DHA is potentially com-
plex and it is difficult to make the case that
there should necessarily be a direct or simple
link between low DHA intake, low plasma DHA
and low brain DHA in humans, let alone in AD.
Especially in the elderly, factors linked to DHA
degradation (peroxidation or loss due to cell
death) in the brain may well be as important in
determining brain DHA levels as the input vari-
ables such as dietary supply of DHA, a trickle of
synthesis, or its transport into the brain. Never-
theless, the optimization of DHA as a supple-
ment for preventing or treating AD depends to
some extent on understanding how DHA is
utilized by the aging brain (table 1), so as to
establish when its use is to be encouraged and
when it is contraindicated.
AD has a major impact on the healthcare deliv-
ery system and has no widely accepted treat-
ment. Exploration of strategies to reduce its risk
and possibly improve its treatment is therefore
an urgent matter. Notwithstanding the reser-
vations we express here about the lack of sup-
port from analysis of brain DHA and weak
support from clinical trials, DHA still stands to
be a key component of such strategies. If the
apparent association between low DHA intake
and increased risk of cognitive decline is really
to bear fruit, several issues need to be kept in
focus. Most importantly and as previously pro-
posed [27, 28], well designed clinical trials are
needed; plausibility and enthusiasm alone can-
not supplant this crucial information.
Table 1. Strengthening the putative link between low docosahexaenoic acid (DHA) and Alzheimer’s disease will
require resolution of the following issues.
1. Do the healthy elderly metabolize x3 fatty acids differently than healthy young adults?
2. Does the brain of the healthy elderly contain less DHA than in healthy young adults?
3. In adult humans, is brain DHA content linked to DHA intake?
4. Is the effect of a DHA supplement on performance of cognitive tests dose dependant?
5. Does the dose of DHA affecting performance on cognitive tests depend on background DHA intake?
6. Do other x3 or x6 polyunsaturates contribute to the mild beneficial effect on cognition presently
attributed to DHA?
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Other issues to be resolved include different
definitions of cognitive function, different time
courses and durations of treatment, and poten-
tial benefits as well as hazards of isolated nutri-
ents versus foods, i.e. DHA supplements versus
higher intake of fish and seafood. Protective
effects against all causes of dementia of as little
as 180 mg/d of DHA have been proposed [7],
yet this amount is 10% or less of the DHA dose
used in two clinical studies [10, 12], and is also
well below even the background DHA intake in
the latter studies (> 500 mg/d). Very low back-
ground DHA intakes, i.e. in the USA, could
hypothetically reduce the dose of DHA needed
to have a clinical benefit, but this still needs to
be established.
Are higher cognitive scores predictive of a bet-
ter DHA effect? Oxidative stress is believed to
play a role in AD so supplementation with a
highly peroxidizable fatty acid like DHA may be
contraindicated in some cases, i.e. perhaps
when the disease is more advanced. Lower
brain AA has been reported in AD and may
contribute to the very mild clinical improve-
ment reported in MCI, so should AA or other
x6 fatty acids [13, 29] be evaluated as a treat-
ment for MCI or AD? EPA is normally virtually
undetectable in the human brain but it may still
have contributed to the mild beneficial effect
on AD symptoms attributed to DHA [10-12].
Perhaps further attention should be paid to the
clinical efficacy in AD or MCI of pure EPA [14].
Finally, we present preliminary data here sug-
gesting that short-term plasma DHA response
to a DHA supplement is significantly higher in
the healthy elderly than in healthy young
adults (figure 1). Much more therefore need to
be done to establish whether healthy aging
changes x3 fatty acid metabolism; such data
will be needed to better interpret DHA effects
in disease states affecting the elderly, especially
AD. Indeed, DHA or other x3 polyunsaturates
are not the only components of fish that could
be responsible for protecting the brain against
cognitive deterioration – marine foods are rich
in other nutrients such as iodine, which may
contribute towards maintaining cognitive
function in the elderly [30].
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24 ± 2 y 74 ± 4 y
Figure 1. Changes in the % composition of docosahexaenoic acid (DHA) in plasma total lipids during 21 days
supplementation with 680 mg/d of (DHA) in elderly versus young adults (74 ± 4 versus 24 ± 2 y old, respectively;
n = 9-10/group). The supplementation period was followed by a 14 day wash-out. Although starting DHA values
were similar and the slopes of the rise and fall of plasma DHA did not differ between the two groups, at d 21, plasma
(DHA) was 42% higher in the elderly (p < 0.05). Compliance was independently verified by adding carbon-13 (13C)
glucose to the DHA capsules and measuring 13C in breath CO2 2 h after the capsules were consumed. Participants
were blinded to the presence of the 13C-glucose on the capsules and to the reason for breath sampling. This study
suggests that the healthy elderly have a higher short-term plasma response to dietary DHA than do healthy young
adults, an effect that is independent of compliance.
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